Liver and spleen surgery for liver cancer with cirrhosis
Part of Blood & lymphatic, Cancer, Digestive system clinical trials.
This study tests whether removing part of the liver along with the spleen during laparoscopic (keyhole) surgery helps improve liver function and the immune system in people with liver cancer and cirrhosis. If you qualify, you may have better surgical outcomes and recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have hepatocellular carcinoma (liver cancer) that is either one tumor 5 cm or smaller, or up to 3 tumors each 3 cm or smaller.
- You have cirrhosis (liver scarring) with an enlarged spleen and a low platelet count (under 80,000).
- Your liver function is good enough for surgery (Child-Pugh class A or B).
- You have not had liver or spleen surgery before, and you do not have other serious health problems or infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether removing an enlarged spleen through keyhole surgery can improve kidney function in people with cirrhosis and an overactive spleen. The trial follows patients for two years to see if the surgery helps protect the kidneys.
This study looks at whether removing an enlarged spleen (splenectomy) in people with cirrhosis can improve their blood fat (lipid) levels over two years. It may help those with low blood counts due to an overactive spleen.
This study tests a special surgery using a nerve-guided technique to remove the enlarged spleen and reduce bleeding risk in people with cirrhosis and portal hypertension. It may help if you have an enlarged spleen and have had bleeding related to liver disease.
This study compares two procedures to treat bleeding from enlarged veins in the esophagus or stomach for people with cirrhosis and an overactive spleen. The goal is to see which approach reduces bleeding risk and improves blood counts over time.
This study tests whether giving a liver transplant to people with cirrhosis and small liver tumors from hepatitis B can help them live longer. It compares outcomes for patients who meet specific tumor size criteria.
This study tests whether giving a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor growth)—before surgery can improve outcomes for people with early-stage liver cancer (a single tumor 2-5 cm) when the surgery is likely to have a narrow margin. You would receive the drugs for a few weeks before your scheduled surgery, and then have the surgery as planned. This approach may help reduce the chance of the cancer coming back.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.